Standard BioTools Schedules Fourth Quarter and Full Year 2024 Earnings Conference Call on February 26, 2025

Rhea-AI Impact

(Neutral)

Rhea-AI Sentiment

(Neutral)

Rhea-AI Summary

Standard BioTools (NASDAQ: LAB) has announced its upcoming fourth quarter and full year 2024 earnings conference call, scheduled for February 26, 2025, after market close. The company will host a conference call and webcast at 4:30 p.m. ET to discuss financial results and operational progress.

Investors can join via phone using (888) 346-3970 for US domestic callers or (412) 902-4297 for international participants. A live webcast will be available on the company's Investor Relations page, with an archived version accessible afterward at investors.standardbio.com.

News Market Reaction – LAB

+3.83%

1 alert

+3.83% News Effect

On the day this news was published, LAB gained 3.83%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

02/12/2025 - 07:00 AM

SOUTH SAN FRANCISCO, Calif., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that it will report fourth quarter and full year 2024 financial results on Wednesday, February 26, 2025, after market close. The company will host a conference call and webcast on the same day at 4:30 p.m. ET to discuss its financial results and operational progress.

Individuals can access the conference call by dialing:

US domestic callers: (888) 346-3970
Outside US callers: (412) 902-4297

Live audio of the webcast will be available online on the Investor Relations page of the Company’s website at Events & Presentations. The webcast will be archived and available on Standard BioTools™ Investor Relations page at investors.standardbio.com.

About Standard BioTools Inc.

Standard BioTools Inc. (Nasdaq: LAB), has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop medicines faster and better. As a leading solutions provider, the company provides reliable and repeatable insights in health and disease using its proprietary SomaScan, mass cytometry and microfluidics technologies, which help transform scientific discoveries into better patient outcomes. Standard BioTools works with leading academic, government, pharmaceutical, biotechnology, plant and animal research and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology and immunotherapy. Learn more at standardbio.com or connect with us on X, Facebook^®, LinkedIn, and YouTube™.

Limited Use Label License and other terms may apply: standardbio.com/legal/salesterms.
Patent and License Information: standardbio.com/legal/notices.
©2025 Standard BioTools Inc. All rights reserved.

Standard BioTools products are provided for Research Use Only. Not for use in diagnostic procedures.

Investor Contact:
David Holmes
ir@standardbio.com

FAQ

When will Standard BioTools (LAB) release Q4 and FY 2024 earnings?

Standard BioTools will release its Q4 and full year 2024 earnings on Wednesday, February 26, 2025, after market close.

What time is Standard BioTools (LAB) Q4 2024 earnings call?

The earnings conference call and webcast is scheduled for 4:30 p.m. ET on February 26, 2025.

How can investors access Standard BioTools (LAB) Q4 2024 earnings call?

Investors can access the call by dialing (888) 346-3970 for US domestic callers or (412) 902-4297 for international callers. A live webcast will also be available on the company's Investor Relations page.